Changes after publication

Changes after publication

February 2014: implementation section updated to clarify that ranibizumab and pegaptanib are recommended as options for treating age-related macular degeneration. Additional minor maintenance update also carried out.

March 2012: minor maintenance

May 2012: re-issued after a change to the patient access scheme

  • National Institute for Health and Care Excellence (NICE)